Therini Bio raises funds to develop neurodegenerative disease therapies
Pharmaceutical Technology
APRIL 28, 2023
Biotechnology company Therini Bio has raised $36m in a Series A financing round to develop fibrin-targeted therapies to treat neurodegenerative and retinal diseases. Therini Bio will use part of the funds to advance its potential first-in-class investigational antibody, THN391, into clinical trials.
Let's personalize your content